Pathos AI raises $237M Series E at $3B valuation led by Bristol Myers Squibb
SiliconANGLE· Maria Deutscher·· 1 hours agoTop DealsAI Score82
Pathos AI raises $237M Series E at $3B valuation led by Bristol Myers Squibb
AI drug development startup Pathos AI closes $237M investment
AI Overview
Pathos AI raised $237 million in a Series E round at a $3 billion valuation, led by Bristol Myers Squibb with returning backers including AstraZeneca.
Why it matters
The round shows pharma companies funding AI drug discovery platforms directly, with Bristol Myers Squibb leading and gaining access to Foundry and licensed patient data.